Biogen Inc. $BIIB Shares Sold by Fisher Asset Management LLC

Fisher Asset Management LLC decreased its position in Biogen Inc. (NASDAQ:BIIB) by 4.1% during the 3rd quarter, Holdings Channel reports. The fund owned 277,285 shares of the biotechnology company’s stock after selling 11,852 shares during the quarter. Fisher Asset Management LLC’s holdings in Biogen were worth $38,842,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Elevation Point Wealth Partners LLC purchased a new stake in shares of Biogen in the 2nd quarter valued at approximately $25,000. Rothschild Investment LLC grew its stake in shares of Biogen by 64.7% during the second quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 88 shares in the last quarter. Accredited Wealth Management LLC increased its holdings in Biogen by 1,233.3% in the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 185 shares during the last quarter. NewSquare Capital LLC increased its holdings in Biogen by 134.6% in the second quarter. NewSquare Capital LLC now owns 244 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 140 shares during the last quarter. Finally, WFA of San Diego LLC acquired a new stake in Biogen in the second quarter valued at $32,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Wall Street Analysts Forecast Growth

BIIB has been the topic of a number of recent analyst reports. Royal Bank Of Canada increased their price objective on Biogen from $217.00 to $233.00 and gave the company an “outperform” rating in a report on Monday, February 9th. Truist Financial upped their price target on Biogen from $190.00 to $193.00 and gave the company a “hold” rating in a report on Monday, February 9th. Wedbush raised their price objective on shares of Biogen from $178.00 to $187.00 and gave the stock a “neutral” rating in a report on Monday, February 9th. Morgan Stanley set a $190.00 price objective on shares of Biogen in a research report on Sunday, February 8th. Finally, Tudor Pickering set a $201.00 target price on shares of Biogen in a research report on Monday, February 9th. Twelve investment analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $205.04.

Biogen Price Performance

BIIB stock opened at $184.02 on Wednesday. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34. The company has a market capitalization of $27.01 billion, a P/E ratio of 20.89, a PEG ratio of 1.49 and a beta of 0.15. The business has a 50 day simple moving average of $182.43 and a 200-day simple moving average of $164.41. Biogen Inc. has a twelve month low of $110.04 and a twelve month high of $202.41.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, beating the consensus estimate of $1.61 by $0.38. The firm had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. Biogen’s revenue for the quarter was down 7.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, equities analysts anticipate that Biogen Inc. will post 15.83 EPS for the current year.

Insider Buying and Selling at Biogen

In related news, insider Priya Singhal sold 2,660 shares of the firm’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the transaction, the insider owned 8,043 shares of the company’s stock, valued at $1,607,232.69. This trade represents a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.18% of the company’s stock.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.